ArticleFrontiers in immunology2026
Repeated-dose toxicity and immunogenicity evaluation of norovirus P particle-based rotavirus vaccine in juvenile cynomolgus monkeys.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Rotavirus remains a major cause of mortality among young children worldwide, underscoring the urgent need for new vaccines. The present study evaluated the repeated-dose toxicity and immunogenicity of a bivalent rotavirus subunit candidate vaccine PP-P[6]/P[8]-VP8 Mix (containing equal amounts of P[6]-VP8 and P[8]-VP8 chimeric antigens) based on norovirus P particles in cynomolgus monkeys. Methods: The monkeys (5 per sex per group) were randomly assigned to a blank control group, an adjuvant control group, and low- and high-dose vaccine groups (60 μg/monkey and 120 μg/monkey). The animals received four intramuscular injections at 4-week intervals, followed by a 6-week recovery period. General behavior, body temperature, body weight, food intake, hematology, serum biochemistry, ophthalmic examination, electrocardiogram, urine analysis, immunogenicity parameters, and pathological examination of the animals were detected. Results: No toxicologically significant abnormalities were observed throughout the study. Histopathological examination showed that there were deposition foci of aluminum hydroxide adjuvant and mild subacute inflammatory reactions at the injection site in the vaccine group. Lymphoid follicle hyperplasia and lymph sinus histiocytosis were observed in the draining lymph nodes, which are typical local immune response manifestations of aluminum adjuvant vaccines. No other adverse pathological changes were found. Conclusions: Our regulatory toxicology study has demonstrated the safety and immunogenicity of PP-P[6]/P[8] - VP8 Mix under the experimental conditions, supporting its entry into clinical research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.